Strategic Initiative

Slingshot members are tracking this corporate initiative:

Advaxis (ADXS) Announces Out-Licensing Deal of Lm-Based Antigen Delivery Technology with SELLAS to Develop a Novel Cancer Immunotherapy Agent

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ADXS

100%
SELLAS Life Sciences Group

100%
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Feb 27, 2017
Projected Implementation:
Q1, 2017
Relevance Tracked Until:
Q1, 2019
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Out-licensing, Lm-based Antigen Delivery Technology, Immunotherapy Agent, Galinpepimut-s